Table 1.
The association between PD-L2 expression and clinical pathological characteristics
| Characteristics | Total N=348 | PD-L2 expression (low) N=205 | PD-L2 expression (high) N=143 | Chi-square | P-value |
|---|---|---|---|---|---|
| Age (years), n (%) | 348 | 205 (58.9) | 143 (41.1) | 1.982 | 0.159 |
| <60 | 142 (40.8) | 90 (25.9) | 52 (14.9) | ||
| ≥60 | 206 (59.2) | 115 (33.1) | 91 (26.1) | ||
| Gender, n (%) | 348 | 205 (58.9) | 153 (41.1) | 0.782 | 0.376 |
| Male | 227 (63.4) | 126 (36.2) | 101 (29.0) | ||
| Female | 131 (36.6) | 79 (22.7) | 42 (12.1) | ||
| Tumor site, n (%) | 348 | 205 (58.9) | 143 (41.1) | 1.927 | 0.165 |
| Colon | 161 (46.3) | 101 (29.0) | 60 (17.2) | ||
| Rectum | 186 (53.4) | 104 (29.9) | 83 (23.9) | ||
| Pathology grading, n (%) | 348 | 205 (58.9) | 143 (41.1) | 2.567 | 0.277 |
| Well-differentiated | 142 (40.8) | 78 (22.4) | 64 (18.4) | ||
| Moderate differentiated | 139 (39.9) | 89 (25.6) | 50 (14.4) | ||
| Poor-differentiated | 67 (19.3) | 38 (10.9) | 29 (8.3) | ||
| Stage (TNM), n (%) | 348 | 205 (58.9) | 143 (41.1) | 9.05 | 0.029 |
| I | 74 (21.3) | 48 (13.8) | 26 (7.5) | ||
| II | 114 (32.8) | 71 (20.4) | 43 (12.4) | ||
| III | 110 (31.6) | 66 (19.0) | 44 (12.6) | ||
| IV | 50 (14.4) | 20 (5.7) | 30 (8.6) | ||
| Tumor volume (mm3), n (%) | 348 | 205 (58.9) | 143 (41.1) | 0.363 | 0.546 |
| <35 | 211 (60.6) | 127 (36.5) | 84 (24.1) | ||
| ≥35 | 137 (39.4) | 78 (22.4) | 59 (17.0) | ||
| Lymph node metastasis, n (%) | 348 | 205 (58.9) | 143 (41.1) | 4.304 | 0.038 |
| Negative | 160 (46.0) | 109 (31.3) | 51 (14.7) | ||
| Positive | 188 (54.0) | 96 (27.6) | 92 (26.4) | ||
| Distant metastasis, n (%) | 338 | 205 (60.7) | 133 (39.3) | 0.3192 | 0.572 |
| Negative | 311 (92.0) | 190 (56.2) | 121 (35.8) | ||
| Positive | 27 (8.0) | 15 (4.4) | 12 (3.6) | ||
| Tumor gross type, n (%) | 268 | 132 (49.3) | 136 (50.7) | 0.944 | 0.624 |
| Mass forming | 81 (30.2) | 49 (18.3) | 32 (11.9) | ||
| Infiltrative | 97 (36.3) | 62 (23.1) | 35 (13.1) | ||
| Ulcerative | 90 (33.6) | 21 (7.8) | 69 (25.7) | ||
| Preoperative CEA (ng/mL), n (%) | 348 | 205 (58.9) | 143 (41.1) | 11.3 | 0.004 |
| <5 | 183 (52.6) | 121 (34.8) | 62 (17.8) | ||
| ≥5 | 165 (47.4) | 84 (24.1) | 81 (23.3) |
Abbreviations: CEA, carcinoembryonic antigen; PD-L2, programmed-death-1-ligand 2.